NewAmsterdam Pharma Co N.V. (NAMS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$457.6M
Cash & Equivalents
$30.6M
Quarterly Burn Rate
45 mo
Est. Cash Runway
$4,122M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07478887 | Impact of the Corrie Lipids Digital Health Program on Lipid Optimization | OTHER | Recruiting | 1,000 |
| NCT06305559 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | PHASE3 | Active Not Recruiting | 300 |
| NCT07219602 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top o... | PHASE3 | Recruiting | 300 |
| NCT06982508 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | PHASE2 | Recruiting | 100 |
| NCT06496243 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | PHASE2 | Recruiting | 69 |
| NCT05972278 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | PHASE1 | Active Not Recruiting | 22 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.